Allergan plc (AGN)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 156.06 / 202.22
Exchange NYSE
Div & Yield N.A. (N.A)

Latest News

The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance

The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance

I have always liked the aggressive management.

Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession

Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession

What's really driving the market, what's making the Nasdaq roar? Tech and science, that's what.

Buffett's Great Airline Escape, Tech Leadership, ECB Wiggle Room

Buffett's Great Airline Escape, Tech Leadership, ECB Wiggle Room

Don't just follow the herd, time your exits and entrances well -- even if it is a big player like Warren Buffett that is leading the charge.

Jim Cramer: I Don't Think Covid-19 Is Invincible

Jim Cramer: I Don't Think Covid-19 Is Invincible

When it's beaten you will wish you own stocks, especially the stocks that are right now lethal to your portfolio.

Jim Cramer: Finding Any Stocks With No Hair?

Jim Cramer: Finding Any Stocks With No Hair?

After a company reports we all know what's wrong, it's immunized. And that's when you can buy.

Jim Cramer: Panicking Never Made Anyone a Dime, but These Will

Jim Cramer: Panicking Never Made Anyone a Dime, but These Will

Here are six companies that should come through in the tough times ahead.

Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff

Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff

Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.

Jim Cramer: Rate Cut No Cure for Coronavirus

Jim Cramer: Rate Cut No Cure for Coronavirus

But don't throw up your arms yet -- here are names that could be golden opportunities.

Coronavirus Spreads, Reducing 'Big Oil', 4 Stocks to Watch, Adding Store Capital

Coronavirus Spreads, Reducing 'Big Oil', 4 Stocks to Watch, Adding Store Capital

Newly confirmed cases of the Covid-19 virus spiked from Hubei Province in China, where the city of Wuhan is located. The number of related deaths increased as well.

Threats to the Marketplace, Dollar Demand, Upcoming Alibaba Earnings

Threats to the Marketplace, Dollar Demand, Upcoming Alibaba Earnings

China-based Alibaba reports quarterly performance Thursday morning. While one might think that an e-commerce type operation could do well in a quarantined environment, it's not quite that easy.

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.

A Technical Strategy for AbbVie as the Broader Market Gets Rocked

A Technical Strategy for AbbVie as the Broader Market Gets Rocked

ABBV could bounce today but there remains the risk of a deeper correction.

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

These companies all could be strong -- even if the 2019 nCoV fear spreads.

Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average

Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average

Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.

This Dividend Aristocrat Is Our Top Pick for 2020

This Dividend Aristocrat Is Our Top Pick for 2020

As it smooths out the wrinkles from 2019, this pharmaceutical manufacturer should have a healthy year.

Individual Investors Are Back! Trading Cisco: Market Recon

Individual Investors Are Back! Trading Cisco: Market Recon

It seemed to happen overnight. People watched. People listened. People cared. About what? Individual stocks.

Allergan Cut to Neutral at UBS

Cash Stashes Dwindle as Markets Crest and Powell Speaks: Market Recon

Cash Stashes Dwindle as Markets Crest and Powell Speaks: Market Recon

Plus, we preview Wednesday's Trump-Erdogan meeting and check out AbbVie's huge debt offering as well as the new Abode-Microsoft connection.

The Price of Fair Trade, Defense Stocks Volatility, Eyes on InMode: Market Recon

The Price of Fair Trade, Defense Stocks Volatility, Eyes on InMode: Market Recon

Investors must understand that the narrative around trade with China has evolved as the two sides work on a 'Phase One' mini-trade deal, but this is about much more than that.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

6 Top Biopharmaceutical Stock Picks You Should Know About

6 Top Biopharmaceutical Stock Picks You Should Know About

The aging population is creating a massive tailwind for companies that provide cutting-edge health care.

The Long Decline in AbbVie Is Over

The Long Decline in AbbVie Is Over

In addition to the yield let's check out the charts of ABBV.

Jim Cramer: Where Can You Still Get Some Growth and a Big Yield?

Jim Cramer: Where Can You Still Get Some Growth and a Big Yield?

Right now, AbbVie is the best way to capitalize on the moment and on the future.

My Outlook for the Market's Major Sectors

* Only three of eleven S&P sectors are viewed as attractive * I am in a risk off state of mind. Back in 2015 I instituted a new regular feature called "Sectors," in which I periodically offered my short-term (6-12 months) price outlook for each of t...

These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.

Evolus Could See Breakout Soon

Evolus Could See Breakout Soon

EOLS appears to have formed a small triangle pattern the past few weeks and a breakout is likely before reaching the apex.

AbbVie: The Right Mixture for the Perfect Stock

AbbVie: The Right Mixture for the Perfect Stock

ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.